Pharma Resources (Shanghai) Co (SZSE:301230) EV-to-EBIT : 113.48 (As of Jun. 24, 2024)

Pharma Resources (Shanghai) Co EV-to-EBIT Chart

Pharma Resources (Shanghai) Co Quarterly Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial															51.61	48.63	55.70	83.22	146.06

Competitive Comparison of Pharma Resources (Shanghai) Co's EV-to-EBIT

For the Biotechnology subindustry, Pharma Resources (Shanghai) Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharma Resources (Shanghai) Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Resources (Shanghai) Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Pharma Resources (Shanghai) Co's EV-to-EBIT falls into.

Pharma Resources (Shanghai) Co EV-to-EBIT Calculation

Pharma Resources (Shanghai) Co's EV-to-EBIT for today is calculated as:

Pharma Resources (Shanghai) Co's current Enterprise Value is ¥3,201.2 Mil.
Pharma Resources (Shanghai) Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥28.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharma Resources (Shanghai) Co  (SZSE:301230) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Pharma Resources (Shanghai) Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Pharma Resources (Shanghai) Co's Enterprise Value for the quarter that ended in Mar. 2024 was ¥4,120.4 Mil.
Pharma Resources (Shanghai) Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥28.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharma Resources (Shanghai) Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Pharma Resources (Shanghai) Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharma Resources (Shanghai) Co (SZSE:301230) Business Description